Literature DB >> 2934362

Ciprofloxacin treatment of systemic salmonella infection in sensitive and resistance mice.

C S Easmon, A Blowers.   

Abstract

Five days therapy with ciprofloxacin (10 mg/kg bd) starting on day 6 after infection with Salmonella typhimurium, significantly reduced mortality in A/J and CBA mice. In CBA mice ciprofloxacin therapy also resulted in significantly lower viable counts of Salm. typhimurium in the livers and spleens of surviving mice at day 36 than was found in untreated mice or those given chloramphenicol. Ciprofloxacin failed to prevent fatal Salm. typhimurium disease in the majority of Balb/C mice, a strain that has no natural immunity to salmonella infection. Death was delayed in ciprofloxacin-treated mice and ciprofloxacin did control the multiplication of salmonellae in liver and spleen within 3 days of commencement.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2934362     DOI: 10.1093/jac/16.5.615

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  7 in total

1.  Oral ciprofloxacin treatment for Salmonella typhimurium infection of normal and immunocompromised mice.

Authors:  H Brunner; H J Zeiler
Journal:  Antimicrob Agents Chemother       Date:  1988-01       Impact factor: 5.191

2.  Treatment of experimental Salmonella typhimurium infection in mice with fleroxacin.

Authors:  T Butler; M R Jacobs; D Farhi
Journal:  Antimicrob Agents Chemother       Date:  1988-05       Impact factor: 5.191

Review 3.  Salmonella typhi and other salmonellas.

Authors:  B K Mandal
Journal:  Gut       Date:  1994-06       Impact factor: 23.059

4.  The proline-rich peptide Bac7(1-35) reduces mortality from Salmonella typhimurium in a mouse model of infection.

Authors:  Monica Benincasa; Chiara Pelillo; Sonia Zorzet; Chiara Garrovo; Stefania Biffi; Renato Gennaro; Marco Scocchi
Journal:  BMC Microbiol       Date:  2010-06-23       Impact factor: 3.605

Review 5.  Ciprofloxacin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use.

Authors:  D M Campoli-Richards; J P Monk; A Price; P Benfield; P A Todd; A Ward
Journal:  Drugs       Date:  1988-04       Impact factor: 9.546

6.  Treatment of experimental salmonellosis in mice with ampicillin-bound nanoparticles.

Authors:  E Fattal; M Youssef; P Couvreur; A Andremont
Journal:  Antimicrob Agents Chemother       Date:  1989-09       Impact factor: 5.191

7.  Tissue compartmentalization enables Salmonella persistence during chemotherapy.

Authors:  Jiagui Li; Beatrice Claudi; Joseph Fanous; Natalia Chicherova; Francesca Romana Cianfanelli; Robert A A Campbell; Dirk Bumann
Journal:  Proc Natl Acad Sci U S A       Date:  2021-12-21       Impact factor: 11.205

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.